R
Retina Centre of Ottawa | Ottawa, Canada
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
APL-2
Dexamethasone
Ranibizumab
Zimura
ANX007
Pegcetacoplan
Avacincaptad pegol
IBE-814
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 8 total trials
The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to...
Active, not recruiting
Geographic Atrophy
Drug: Vonaprument
Other: Sham Administration
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...
Enrolling
Wet Age-related Macular Degeneration
WetAMD
Genetic: ABBV-RGX-314 Dose 1
Biological: Aflibercept (EYLEA®)
Locations recently updated
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tiss...
Enrolling
Neovascular Age-related Macular Degeneration
Drug: Surabgene Lomparvovec (ABBV-RGX-314)
Drug: Ranibizumab Control
Trial sponsors
A
A
I
R
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems